Noa Dagan

Noa Dagan, PhD

Director of Patient Data Core, DBMI Clalit Collaboration

Noa Dagan is a public health physician and medical informatics researcher. She holds an MD and an MPH from the Hebrew University and a Ph.D. in Computer Science from Ben-Gurion University. She completed her postdoc in the Department of Biomedical Informatics at Harvard Medical School.

Dr. Dagan heads the AI-driven Medicine Department at Clalit Innovation (Clalit is Israel's largest integrated healthcare organization, covering over 50% of the Israeli population). Her responsibilities include developing and implementing digital healthcare solutions to promote preventive, proactive, and personalized medicine. She leads the entire lifecycle of AI-driven interventions, from conception, through machine-learning modeling, to implementation in medical practice.

Dr. Dagan is also the co-director of the Digital Health Lab at the Software and Information Systems Engineering Department at Ben-Gurion University. Her research focuses on prediction models, algorithmic fairness, and causal inference based on real-world data.

The association between real-time reverse transcriptase polymerase chain reaction cycle threshold values, symptoms and disease severity among COVID-19 patients in the community: a retrospective cohort study.
Authors: Makov-Assif M, Krispin S, Ben-Shlomo Y, Holander T, Dagan N, Balicer R, Barda N.
Infect Dis (Lond)
View full abstract on Pubmed
The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines.
Authors: Barda N, Dagan N.
Clin Microbiol Infect
View full abstract on Pubmed
Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
Authors: Katz MA, Harlev EB, Chazan B, Chowers M, Greenberg D, Peretz A, Tshori S, Levy J, Yacobi M, Hirsch A, Amichay D, Weinberger R, Dor AB, Taraday EK, Reznik D, Chayat CB, Sagas D, Zvi HB, Berdinstein R, Rashid G, Avni YS, Mandelboim M, Zuckerman N, Rainy N, Akriv A, Dagan N, Kepten E, Barda N, Balicer RD.
Vaccine
View full abstract on Pubmed
Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex.
Authors: Dagan N, Barda N, Balicer RD.
N Engl J Med
View full abstract on Pubmed
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Authors: Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD.
Lancet
View full abstract on Pubmed
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
Authors: Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R.
N Engl J Med
View full abstract on Pubmed
Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.
Authors: Reis BY, Barda N, Leshchinsky M, Kepten E, Hernán MA, Lipsitch M, Dagan N, Balicer RD.
N Engl J Med
View full abstract on Pubmed
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
Authors: Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, Hernán MA, Lipsitch M, Hernandez-Diaz S, Reis BY, Balicer RD.
Nat Med
View full abstract on Pubmed
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Authors: Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD.
N Engl J Med
View full abstract on Pubmed
MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population.
Authors: Ben Shachar S, Barda N, Manor S, Israeli S, Dagan N, Carmi S, Balicer R, Zisser B, Louzoun Y.
J Clin Immunol
View full abstract on Pubmed